Section 1. General Pharmacokinetic and Pharmacodynamic Principles of
Psychopharmacological Agents.- 1. Pharmacokinetic Properties.- 2. Pharmacodynamic
Properties.- 3. PET Scan and Other Biomarkers.- 4. Population
Pharmacokinetics.- 5. Drug Transporters (esp. Blood Brain Barrier).- 6. Pharmacogenomics.-
Section 2. Clinical Pharmacokinetics and Pharmacodynamics of
Psychopharmacological Drug Classes.- 7. Antipsychotics – oral typical agents,
oral atypical agents, and long-acting injectable (LAI) antipsychotics.- 8. Mood
Stabilizers.- 9. Antidepressants – tricyclics, selective serotonergic reuptake
inhibitors, serotonergic noradrenergic reuptake inhibitors, monoamine oxidase
inhibitors, and other antidepressants.- 10. Benzodiazepines and Other Sedative
Hypnotics/Anxiolytics.- 11. Opioid Analgesics.- 12. Stimulants and Other
Non-Stimulants for ADHD.- 13. Cholinesterase Inhibitors and Other Antidementa
Agents.- 14. Anti-Addiction Agents.- 15. Anesthetics.- Section 3. Clinically
Significant Drug Interactions With Psychopharmacological Agents.- 16.
Antipsychotics.- 17. Mood Stabilizers.- 18. Antidepressants.- 19.
Benzodiazepines and Other Sedative Hypnotics/Anxiolytics.- 20. Opioid
Analgesics.- 21. Stimulants and Other Non-Stimulants for ADHD.- 22. Cholinesterase
Inhibitors and Other Antidementa Agents.- 23. Anti-Addiction Agents.- 24.
Anesthetics.
Michael
W. Jann, Pharm.D., FCP, FCCP is Professor and Chair for the Department of
Pharmacotherapy at the University of North Texas System College of Pharmacy
(UNTSCP) located at the UNT Health Sciences Center (UNTHSC). Professor Jann
received his Doctor of Pharmacy degree from the University of Southern California
and post-doctoral training in mental health pharmacy practice at the University
of Tennessee Memphis College of Pharmacy. He has published over 230 peer-review
articles, abstracts, and book chapters and served as a primary investigator for
numerous clinical trials in psychopharmacology. Professor Jann serves on the
editorial boards of six peer-review scientific journals including CNS Drugs,
Molecular Diagnostics and Therapeutics, The Scientific World Journal –
Pharmacology Section, The Consultant Pharmacist, Journal of Clinical
Pharmacology, and Journal of Pharmacy Practice.
Scott R. Penzak, Pharm.D., FCP, is Professor and
Vice Chair for the Department of Pharmacotherapy at the University of North
Texas System College of Pharmacy (UNTSCP) located at the UNT Health Sciences
Center (UNTHSC). Professor Penzak received his Doctor of Pharmacy degree from
Wayne State University and completed his post-doctoral training in infectious
diseases at the University of Arkansas for Medical Science (UAMS). Prior to
UNTSCP, he was the Director of the Clinical Pharmacokinetics Laboratory at the NIH. He has published over 150 peer-review articles,
abstracts, and book chapters, and served as a principal investigator on
numerous pharmacokinetic and pharmacogeneticstudies. Professor Penzak serves on
the editorial boards of three peer-review scientific journals including Journal
of Clinical Pharmacology, Pharmacotherapy, and the International Journal of
Pharmacokinetics.
Lawrence J. Cohen, PharmD, BCPP, FASHP, FCCP,
FCP, FNAP is currently Professor of Pharmacotherapy at the University of North
Texas System College of Pharmacy. Examples of Professor Cohen’s previous
service include, Global Director of CNS Research for Kendle International,
Director of the Office of Clinical Trials for University of Cincinnati, and
Director of Pharmaceutical Services for the Oklahoma Department of Mental
Health and Substance Abuse Services. Professor Cohen received his Doctor of Pharmacy
degree and post-doctoral training in psychiatric pharmacy from University of
Southern California School of Pharmacy. Professor Cohen has been a Board
Certified Psychiatry Pharmacist since the specialty was recognized. His relevant service on Editorial Boards include Current
Psychiatry, Innovations in Clinical Neuroscience, Primary Care Companion of the
Journal of Clinical Psychiatry, Drug Benefit Trends, Journal of the American
Medical Directors Association, CNS News and Pharmacy Practice News.
This
book is a comprehensive resource on psychotropic medications, detailing the
latest methods for defining their characteristics, their use in different
patient populations, and drug-drug interactions; an important collection of
information forclinicians, students, researchers, and members of the
pharmaceutical industry alike.
The
first section provides the foundational principles of these drugs. Mathematical
modeling of parameters that affect their entryto,and exit from, the central
nervous system (CNS) compartment are presented on an individual basis and then
applied to target populations with specific disease states. Methods and
characteristics that inform the transfer of these drugs from the laboratory
bench to use in patient care are discussed, including imaging techniques,
genetics and physiological barriers, such as the blood-brain barrier. The second
section describes the characteristics of specific agents,nominally arranged
intodifferent therapeutic categories and with reference crossover use in
different disease states. The pharmacologic characteristics of different drug
formulations are explored in the context of their ability to improve patient
adherence. The third section focuses on drug-drug interactions.Psychotropic medications
from different categories are frequently prescribed together,or alongside
medications used to treat comorbid conditions, and the information provided is
directly relevant to the clinic, as a result.
The
clinical application of pharmacokinetics and pharmacodynamics of CNS agents has
made significant progress over the past 50 years and new information is reported
by numerous publications in psychiatry, neurology, and pharmacology.Our
understanding of the interrelationship between these medications, receptors,
drug transporters, as well as techniques for measurement and monitoring their
interactions,isfrequently updated. However, with information presented on a
host of different platforms, and in different formats, obtaining the full
picture can be difficult. This title aims to collate this information into a
single source that can be easily interpreted and applied towards patient care
by the clinical practitioner, and act as a reference for all others who have an
interest in psychopharmacological agents.